Cargando…
Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study
OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267805/ https://www.ncbi.nlm.nih.gov/pubmed/37226045 http://dx.doi.org/10.1002/acr2.11550 |
_version_ | 1785059004094873600 |
---|---|
author | DerSarkissian, Maral Gu, Yuqian M. Duh, Mei Sheng Benson, John Huang, Shirley P. Averell, Carlyne Vu, Jensen Wang, Min‐Jung Bell, Christopher F. |
author_facet | DerSarkissian, Maral Gu, Yuqian M. Duh, Mei Sheng Benson, John Huang, Shirley P. Averell, Carlyne Vu, Jensen Wang, Min‐Jung Bell, Christopher F. |
author_sort | DerSarkissian, Maral |
collection | PubMed |
description | OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real‐World Data Adjudicated Claims‐US database (January 2006 to July 2019) had continuous enrollment during the 6‐month preindex (baseline) and 12‐month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The “OCS‐initiator cohort” comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6‐month periods of more than 5 mg/day of OCS use (0, 1, 2). The “no‐OCS‐use cohort” comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period. RESULTS: Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761‐$7368], $19,149 [95% CI: $16,954‐$21,471], $28,985 [95% CI: $25,546‐$32,885]). HCRU incidence rates were significantly greater for all OCS‐initiator exposure categories (n = 16,216) versus the no‐OCS‐use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19‐1.24], 1.39 [1.34‐1.43], 1.66 [1.60‐1.73]). OCS‐related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system. CONCLUSION: Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use. |
format | Online Article Text |
id | pubmed-10267805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wiley Periodicals, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102678052023-06-15 Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study DerSarkissian, Maral Gu, Yuqian M. Duh, Mei Sheng Benson, John Huang, Shirley P. Averell, Carlyne Vu, Jensen Wang, Min‐Jung Bell, Christopher F. ACR Open Rheumatol Original Articles OBJECTIVE: To characterize health care resource utilization (HCRU), health care costs, and adverse events (AEs) among patients with systemic lupus erythematosus (SLE) initiating oral corticosteroids (OCS) versus patients without OCS use. METHODS: In this retrospective cohort study (GSK Study 213061), eligible patients (aged ≥5 years at first OCS claim) with SLE from the IQVIA Real‐World Data Adjudicated Claims‐US database (January 2006 to July 2019) had continuous enrollment during the 6‐month preindex (baseline) and 12‐month postindex (observation) periods and one or more inpatient or emergency department SLE diagnosis codes or two or more outpatient SLE diagnosis codes during baseline. The “OCS‐initiator cohort” comprised patients with one or more OCS pharmacy claims during the study period and no evidence of preindex OCS use and was classified into three exposure categories based on the number of 6‐month periods of more than 5 mg/day of OCS use (0, 1, 2). The “no‐OCS‐use cohort” comprised patients without OCS claims, although patients may have received OCS prior to the study period. Clinical and economic outcomes were reported over the observation period. RESULTS: Adjusted health care costs differed significantly ($6542 [95% confidence interval (CI): $5761‐$7368], $19,149 [95% CI: $16,954‐$21,471], $28,985 [95% CI: $25,546‐$32,885]). HCRU incidence rates were significantly greater for all OCS‐initiator exposure categories (n = 16,216) versus the no‐OCS‐use cohort (n = 11,137; adjusted incidence rate ratios [95% CI]: 1.22 [1.19‐1.24], 1.39 [1.34‐1.43], 1.66 [1.60‐1.73]). OCS‐related AEs were experienced by 67.1% to 74.1% of patients with OCS initiation, most commonly affecting the immune system. CONCLUSION: Within 12 months of OCS initiation, patients with SLE experienced substantial clinical and economic burden, which may imply a need to minimize OCS use. Wiley Periodicals, Inc. 2023-05-24 /pmc/articles/PMC10267805/ /pubmed/37226045 http://dx.doi.org/10.1002/acr2.11550 Text en © 2023 GSK and The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles DerSarkissian, Maral Gu, Yuqian M. Duh, Mei Sheng Benson, John Huang, Shirley P. Averell, Carlyne Vu, Jensen Wang, Min‐Jung Bell, Christopher F. Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title | Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title_full | Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title_fullStr | Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title_full_unstemmed | Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title_short | Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study |
title_sort | clinical and economic burden in patients with systemic lupus erythematosus during the first year after initiating oral corticosteroids: a retrospective us database study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267805/ https://www.ncbi.nlm.nih.gov/pubmed/37226045 http://dx.doi.org/10.1002/acr2.11550 |
work_keys_str_mv | AT dersarkissianmaral clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT guyuqianm clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT duhmeisheng clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT bensonjohn clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT huangshirleyp clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT averellcarlyne clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT vujensen clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT wangminjung clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy AT bellchristopherf clinicalandeconomicburdeninpatientswithsystemiclupuserythematosusduringthefirstyearafterinitiatingoralcorticosteroidsaretrospectiveusdatabasestudy |